Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes - PubMed (original) (raw)

Review

Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes

Carolyn F Deacon. Expert Opin Investig Drugs. 2007 Apr.

Abstract

Sitagliptin is a once-daily, orally active, competitive and fully reversible inhibitor of dipeptidyl peptidase 4, the enzyme that is responsible for the rapid degradation of the incretin hormone glucagon-like peptide-1. It is the first in this new class of antihyperglycaemic agents to gain regulatory approval for the treatment of Type 2 diabetes, both as a monotherapy and for use in combination with metformin or a thiazolidinedione. In clinical trials of < or = 1-year duration, sitagliptin improves glycaemic control by reducing both fasting and postprandial glucose concentrations, leading to clinically meaningful reductions in glycosylated haemoglobin levels. It is safe and well tolerated, with a side-effect profile that is similar to that of the placebo, a low incidence of hypoglycaemia and body weight neutrality. Further clinical experience with sitagliptin will reveal its long-term durability, safety and efficacy.

PubMed Disclaimer

Cited by

Network pharmacology, molecular docking, and molecular dynamics simulation to elucidate the mechanism of anti-aging action of Tinospora cordifolia.
Bisht A, Tewari D, Kumar S, Chandra S. Bisht A, et al. Mol Divers. 2024 Jun;28(3):1743-1763. doi: 10.1007/s11030-023-10684-w. Epub 2023 Jul 13. Mol Divers. 2024. PMID: 37439907 Review.
Sitagliptin-Dependent Differences in the Intensity of Oxidative Stress in Rat Livers Subjected to Ischemia and Reperfusion.
Trocha M, Krzystek-Korpacka M, Merwid-Ląd A, Nowak B, Pieśniewska M, Dzięgiel P, Gomułkiewicz A, Kowalski P, Diakowska D, Szeląg A, Sozański T. Trocha M, et al. Oxid Med Cell Longev. 2019 Oct 31;2019:2738605. doi: 10.1155/2019/2738605. eCollection 2019. Oxid Med Cell Longev. 2019. PMID: 31781329 Free PMC article.
Development of a 13C Stable Isotope Assay for Dipeptidyl Peptidase-4 Enzyme Activity A New Breath Test for Dipeptidyl Peptidase Activity.
Yazbeck R, Jaenisch S, Squire M, Abbott CA, Parkinson-Lawrence E, Brooks DA, Butler RN. Yazbeck R, et al. Sci Rep. 2019 Mar 20;9(1):4906. doi: 10.1038/s41598-019-41375-y. Sci Rep. 2019. PMID: 30894647 Free PMC article.
Pharmacology of dipeptidyl peptidase-4 inhibitors and its use in the management of metabolic syndrome: a comprehensive review on drug repositioning.
Rameshrad M, Razavi BM, Ferns GAA, Hosseinzadeh H. Rameshrad M, et al. Daru. 2019 Jun;27(1):341-360. doi: 10.1007/s40199-019-00238-7. Epub 2019 Jan 23. Daru. 2019. PMID: 30674032 Free PMC article. Review.
Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study.
Dagogo-Jack S, Liu J, Eldor R, Amorin G, Johnson J, Hille D, Liao Y, Huyck S, Golm G, Terra SG, Mancuso JP, Engel SS, Lauring B. Dagogo-Jack S, et al. Diabetes Obes Metab. 2018 Mar;20(3):530-540. doi: 10.1111/dom.13116. Epub 2017 Oct 23. Diabetes Obes Metab. 2018. PMID: 28921862 Free PMC article. Clinical Trial.

Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes - PubMed (original) (raw)